There are very few people who are willing to discuss the
pending mega merger between American publically traded agro
biotech company Monsanto, and the German megalithic life
science and pharma company Bayer. The deal is worth a reported
$66 billion and has unsurprisingly piqued the interest of
antitrust agencies across the world.
After some research, I saw some (many) fairly crucial issues
with the deal. For one thing, the statistics suggest that
Monsanto already owns far more than what should be considered
as acceptable level in several key industries like cotton, soy
or corn. Why is it acceptable for...